Barclays raised the firm’s price target on Eli Lilly to $630 from $590 and keeps an Overweight rating on the shares post the Q3 report. The company offered supportive commentary on supply, confidence on obesity approval, and absence of concerns on growth outlook “should keep momentum going,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Delivers Robust Q3 Sales Growth
- Eli Lilly cuts FY23 EPS view to $6.50-$6.70 from $9.70-$9.90, consensus $6.72
- Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
- Eli Lilly reports Q3 EPS 10c, consensus (15c)
- Notable companies reporting before tomorrow’s open